Praxis Precision Medicines Reports Positive Trial Results

Praxis Precision Medicines announced positive results from the EMBRAVE Part A trial for elsunersen in patients with SCN2A developmental and epileptic encephalopathy. The treatment demonstrated a significant placebo-adjusted seizure reduction of 77%. A substantial 71% of treated patients achieved over a 50% reduction in seizures. These findings represent a promising advancement in treating this rare neurological disorder and suggest potential efficacy for elsunersen.